苦参黄酮联合卡托普利对糖尿病大鼠心肌病变的改善作用

doi:10.13481/j.1671-587x.20160417

摘要/Abstract

摘要：

目的：探讨苦参黄酮与卡托普利联合应用对2型糖尿病心肌病模型大鼠心肌病变的改善作用，初步阐明其改善大鼠心肌纤维化的作用机制。方法：在100只清洁级雄性Wistar 大鼠中随机选取15只为正常组，其余大鼠以高脂、高糖饲料饲养配合一次性腹腔注射小剂量链脲佐菌素（STZ，30mg·kg^-1）的方法，建立实验性2型糖尿病心肌病大鼠模型，共72只成模。按血糖水平选取60只大鼠，随机分为模型组、卡托普利组、苦参黄酮组和苦参黄酮联合卡托普利组，每组15只，灌胃给药8周后，观察各组大鼠的体质量、心脏指数和血清中乳酸脱氢酶（LDH）、肌酸激酶-MB（CK-MB）活性及心肌组织中一氧化氮合酶（iNOS）、一氧化氮（NO）、Ⅰ型胶原及Ⅲ型胶原的水平。结果：与正常组比较，模型组大鼠体质量下降（P < 0.01），心脏指数增加（P < 0.01），血清中LDH和CK-MB活性增加（P < 0.01），心肌组织中iNOS和 NO水平降低（P < 0.05），ColⅠ和ColⅢ水平增加（P < 0.05或P < 0.01）。与模型组比较，各给药组大鼠体质量增加（P < 0.05），心脏指数下降（P < 0.05），血清中LDH和CK-MB活性降低（P < 0.05），心肌组织中iNOS和NO水平增加（P < 0.05或P < 0.01），ColⅠ和ColⅢ水平降低（P < 0.05或P < 0.01），且苦参黄酮联合卡托普利组改善效果好于单独用药组（P < 0.05）。结论：苦参黄酮与卡托普利联合应用对2型糖尿病模型大鼠心肌病变有一定的改善作用，其可能的机制是通过减少心肌损伤改善糖尿病心肌病。

关键词: 糖尿病, 2型, 心肌疾病, 苦参黄酮, 卡托普利

Abstract:

Objective: To study the improvement effect of Sophora Flavones combined with captopril on the rat diabetic cardiomyopathy,and to clarify its mechanisms of improving the myocardial fibrosis. Methods: Fifteen rats were selected randomly from 100 male Wistar rats as normal group.The other rats were fed with high fat and high sugar food and intraperitoneally injected with small dose of streptozotocin (30 mg·kg^-1) all at once to establish type 2 diabetes mellitus cardiomgopathy models.Then 72 rat models with type 2 diabetic cardiomyopathy were set up in which 60 rats were selected according to the blood glucose levels and divided into model group,captopril group,Sophora Flavones group, and Sophora Flavones combined with captopril group (combination group)(n=15).8 weeks after intragastric administration,the weights,the cardiac indexes,the activities of serum creatine kinase-MB(CK-MB),lactate dehydrogenase(LDH),and the contents of nitric oxide(NO),nitric oxide synthase(iNOS),collagen Ⅰ(Col Ⅰ) and collagen Ⅲ(Col Ⅲ) of the rats in various groups were detected. Results: Compared with normal group,the weight of the rats in model group was decreased and the cardiac index was increased(P < 0.01), the activities of serum LDH and CK-MB were increased(P < 0.01),the contents of iNOS and NO in the myocardium tissue of the rats in model group were decreased(P < 0.01),and the contents of Col Ⅰ and col Ⅲ were increased(P < 0.05 or P < 0.01).Compared with model group,the weights and the cardiac indexes of the rats in medication groups were decreased(P < 0.05), the activities of serum LDH and CK-MB were decreased(P < 0.05 or P < 0.01), the contents of iNOS and NO in the myocardium tissue were increased(P < 0.05),and the contents of Col Ⅰ and Col Ⅲ were decreased(P < 0.05 or P < 0.01).The effect of combination group was better than single medication groups(P < 0.05). Conclusion: Combination of Sophora Flavones and captopril has a improvement effect on the rat type 2 diabetic cardiomyopathy,and its mechanism may be related to reducing the myocardial injury to improve diabetic cardiomyopathy

Key words: diabeticmellitus,type 2, cardiomyopathy, Sophora Flavones, captopril

中图分类号:

R285.5

常影, 路倩, 王燕, 王艳春. 苦参黄酮联合卡托普利对糖尿病大鼠心肌病变的改善作用[J]. 吉林大学学报(医学版), 2016, 42(04): 721-724.

CHANG Ying, LU Qian, WANG Yan, WANG Yanchun. Improvement effect of Sophora Flavones combined with captopril on diabetic cardiomyopathy of rats[J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 721-724.

参考文献

[1] Isfort M,Stevens SC,Schaffer S,et al.Metabolic dysfunction in diabetic cardiomyopathy [J]. Heart Fail Rev,2014,19(1):35-48.

[2] Battiprolu PK,Lopez-Crisosto C,Wang ZV,et al.Diabetic car-diomyopathy and metabolic remodeling of the heart[J].Life Sci,2013,92(11):609-615.

[3] 闫德祺,闫英男,阿力木·买买提,等.苦参活性成分的抗肿瘤作用机制研究进展[J].现代生物医学进展,2014,14(24):4776-4779.

[4] 刘群.实验性2型糖尿病心肌病大鼠模型建立的方法[J].临床心血管病杂志,2014,30(3):254-257.

[5] 董世芬,洪缨,樊江波,等.实验性2 型糖尿病心肌病大鼠模型的建立与评价[J].中国实验动物学报,2009,17(4):245-251.

[6] Fang ZY,Prins JB,Marwick TH.Diabetic cardiomyopathy:evidence,mechanisms,and therapeutic implications[J].Endocr Rev,2004,25(4): 543 -547.

[7] Mandavia CH,Pulakat L,DeMarco V,et al.Over-nutrition,obesity and metabolic cardiomyopathy[J].Metabolism,2012,61(9):1205-1210.

[8] Hayden MR,Tyagi SC.Myocardial redox stress and remodeling inmetabolic syndrome,type 2 diabetes mellitus,and congestive heart failure[J].Med Sci -Monit,2003,9(7):SR35-52.

[9] Collier P,McDonald KM. The role of renin angiotensin system intervention in stage B heart failure [J].Heart Fail Clin,2012,8(2):225-236.

[10] Balliprolu PK,Lopez-Crisoslo C,Wang ZV,et al.Diabelic cardiomyopathy and melabolic of the heart [J].Life Sci,2013,92(11):609-615.

[11] Adameova A,Dhalla NS.Role of microangiopathy in diabertic cardiomyopathy [J].Heart Fail Rev,2014,19(1):25-33.

[12] Fancher IS,Dick GM,Hollander JM.Diabetes mellites reduces the function and expression of ATP-dependent K⁺ channels in cardiac mitochondria[J].Life Sci,2013,92(11):664-668.

[13] Liu JW,Liu D,Cui KZ,et al.Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy[J].Biochem Biophys Res Commun,2012,427(3):441-443.

[14] Bell DS.Diabetic cardiomyopathy[J].Diabetes Care,2003,26(10):2791-2795.

[15] 席晓慧,王福文,牟艳玲.糖尿病心肌病的药物治疗研究进展[J].山东医药,2014,54(5):93-95.